Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492566 | 0.93 | MAPK1 (0.37) | MAPK1SIRT2SIRT1SIRT3NPSR1 | |
| SCHEMBL6502329 | 0.81 | AKT3 (0.35) | SIRT2SIRT1SIRT3AKT3 | |
| SCHEMBL6503414 | 0.80 | MAPK1 (0.38) | MAPK1SIRT2SIRT1SIRT3NPSR1 | |
| SCHEMBL7508488 | 0.77 | NPSR1 (0.35) | MAPK1NPSR1HPGDTSHRATM | |
| SCHEMBL6503418 | 0.77 | NPSR1 (0.40) | MAPK1SIRT2SIRT1SIRT3NPSR1 | |
| SCHEMBL22268382 | 0.73 | NPSR1 (0.47) | MAPK1SIRT2SIRT1SIRT3NPSR1 | |
| SCHEMBL6494906 | 0.72 | MAPK1 (0.39) | MAPK1NPSR1L3MBTL1HTR2CACKR3 | |
| SCHEMBL28767269 | 0.72 | NPSR1 (0.46) | MAPK1SIRT2SIRT1SIRT3NPSR1 | |
| SCHEMBL6494913 | 0.70 | KMT2A (0.36) | MAPK1SIRT2SIRT1SIRT3NPSR1 | |
| SCHEMBL5298045 | 0.70 | CA14 (0.31) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250743-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | LEHN JEAN-MARIE | 2005-11-10 | — | — | US | claimed |
| US-6610702-B2 | Supplying oxygen to tissues, organs | GMP OXYCELL, INC. | 2003-08-26 | — | — | US | claimed |
| US-20020173494-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | GMP OXYCELL, INC. | 2002-11-21 | — | — | US | claimed |
| US-20050250743-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | LEHN JEAN-MARIE | 2005-11-10 | — | — | US | disclosed |
| US-6960594-B2 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | SHIRE BIOCHEM INC. (CA) | 2005-11-01 | — | — | US | disclosed |
| EP-1091952-B1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | IAF BIOCHEM INT (CA) | 2003-10-29 | — | — | EP | disclosed |
| US-6610702-B2 | Supplying oxygen to tissues, organs | GMP OXYCELL, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020173494-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | GMP OXYCELL, INC. | 2002-11-21 | — | — | US | disclosed |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | BIOCHEM PHARMA INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1091952-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000486-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250743-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | ITPA, PPIP5K2, INPP5B | MAPK1 4330/4885SIRT2 2095/4885SIRT1 2341/4885 |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | ITGB5, ITGB2, ITGA2 | MAPK1 4153/4885SIRT2 242/4885SIRT1 437/4885 |
| US-20020173494-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | ITPA, PPIP5K2, INPP5B | MAPK1 4330/4885SIRT2 2095/4885SIRT1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.